Michelle Fan

TL;DR: With the convenience of a subcutaneous injection and no requirement for renal monitoring, denosumab represents a potential treatment option for patients with bone metastases.

TL;DR: In postmenopausal women with osteoporosis who were at high risk for fracture, romosozumab treatment for 12 months followed by alendronsate resulted in a significantly lower risk of fracture than alendronate alone.

TL;DR: A single s.c. dose of denosumab given to patients with multiple myeloma or bone metastases from breast cancer was well tolerated and reduced bone resorption for at least 84 days, and the effect diminished progressively through follow-up.

TL;DR: In women with nonmetastatic breast cancer and low bone mass who were receiving adjuvant aromatase inhibitor therapy, twice-yearly administration of denosumab led to significant increases in BMD over 24 months at trabecular and cortical bone, with overall AE rates similar to those of placebo.

TL;DR: Subcutaneous denosumab may be similar to IV BPs in suppressing bone turnover and reducing SRE risk in patients with breast cancer-related bone metastases not previously treated with intravenous bisphosphonates (IV BPs).